Tag archive for ‘Cryoport 2Q sales’
Cryoport: Quick Take on 2Q Results (CYRX, $20.18, Buy)
Cryoport reported a very strong quarter as sales increased by 83%. The key biopharma segment increased sales by 81%. This was led by a 326% increase in sales stemming from support of the commercial CAR-T products, Kymriah and Yescarta. Some $600,000 of incremental sales were recorded from the acquisition of Cryogene which closed on May […]